

Home > About us > **Our History**

Our Successful Journey

True to the origin of our name, Metamorphosis, MorphoSys has transformed from an R&D technology provider into a global commercialstage biopharmaceutical company.

1992

MorphoSys founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr. Andreas Plückthun

1994

Invention of the HuCAL Concept, synthetic library consisting of human antibody sequences for the generation of highly specific, fully human antibodies. Inventor: Achim Knappik, Dr. Simon Moroney, Prof. Dr. Andreas Plückthun (and others)

1997

Move to IZB Gründerzentrum with ~30 employees; first partnership with Pharmacia & Upjohn

1999

MorphoSys is listed on the Frankfurt stock exchange; partnership with Bayer

2000

Move to our own building in Martinsried, ~100 employees

2000-2007

Growth through partnerships: Novartis, Janssen, Schering-Plough, Pfizer, Merck

Since 2007

Own drug development, e.g. with Xencor, GSK and others

2016

Move to new building in Planegg: state-of-the-art office and lab, unifying all teams under one roof

2017

Tremfya[®] is the first drug based on MorphoSys' antibody technology to receive regulatory approval. Developed and marketed by Janssen for the treatment of plaque psoriasis

2018

MorphoSys is listed on NASDAQ; MorphoSys US Inc. is established; MorphoSys and I-Mab enter strategic development and commercialization agreement for MOR210/TJ210

2019

Jean-Paul Kress appointed as MorphoSys CEO in September

January 2020

MorphoSys and Incyte enter into collaboration and licensing agreement to further develop and commercialize tafasitamab globally

July 2020

The U.S. Food and Drug Administration (FDA) grants accelerated approval for Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma

November 2020


MorphoSys and Cherry Biolabs entered into a licensing agreement for innovative, multispecific Hemibody technology; MorphoSys and Xencor enter into collaboration exploring further combinations with tafasitamab and Xencor's CD20xCD3 bispecific plamotamab

July 2021

Acquisition of Constellation Pharmaceuticals, a U.S. biotech company that adds exciting, pioneering science and two new product candidates to our pipeline

August 2021

Conditional approvals for Minjuvi[®] (tafasitamab) in the European Union and Canada in combination with lenalidomide in patients with a certain type of lymphoma



By clicking "Accept All Cookies", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. <u>Privacy Principles</u>

Cookies Settings

Reject All Cookies

Accept All Cookies

X